相关实验视频

Updated: Sep 20, 2025

Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model

Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model

Published on: October 16, 2017

通过 CD44 向的 RIP3 基因传递策略,通过亡和免疫调节增强癌症治疗

Sang Eun Kim¹, Soyeon Bak², Jung Hee Park¹

¹Department of Biomedical Science, Program in Biomedical Science & Engineering, and College of Medicine, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.

Journal of controlled release : official journal of the Controlled Release Society

|May 28, 2025

概括

一种新型的pH敏感聚合物CA通过向RIP3 (受体相互作用蛋白激酶3) 并增强抗瘤免疫力,增强了用于癌症治疗的基因传递. 这种策略有效触发亡并刺激免疫细胞对瘤的活性.

科学领域:

生物技术和生物医学工程生物技术和生物医学工程
癌症治疗和免疫疗法
基因传递系统是基因传递系统.

背景情况:

受体相互作用蛋白激酶3 (RIP3) 介导的亡是癌症治疗的一个有希望的途径,因为它有能力增强瘤免疫性.
准RIP3提供了一种潜在的策略,可以诱导免疫细胞死亡并刺激抗瘤免疫反应.
开发高效和有针对性的基因传递系统对于有效的癌症基因治疗至关重要.

研究的目的:

合成和评估一个pH敏感的聚合物 (CA),用于向的RIP3基因传递在癌症治疗中.
调查基于CA的系统的瘤向能力和基因传递效率.
评估RIP3基因传递的治疗疗效和免疫调节效应,其介导者是CA.

主要方法:

通过将aminopropyl imidazole (API) 与chondroitin sulfate (CHS) 结合,合成一种对pH值敏感的聚合物 (CA).
通过CD44受体相互作用和pH敏感的内体逃逸来评估CA的准能力.
在小鼠癌症模型中评估RIP3/MLKL信号通路激活,瘤选择性和治疗疗效 (A549异种移植,LLC1 orthotopic).

主要成果:

合成的CA聚合物证明有效向过度表达CD44的癌细胞,并由于其pH敏感性,促进了有效的内体细胞逃逸.
通过CA介导的RIP3 (CA-PEI/RIP3) 输送显著增加了RIP3/MLKL信号通路的激活,并且在体内证明了瘤选择性和切除功效.
CA-PEI/RIP3治疗增强了抗瘤免疫反应,其证据是树突细胞的化,CD4+和CD8+T细胞的透以及瘤组织和淋巴结中的成熟树突细胞的增加.

结论:

开发的基于CA的基因传递系统通过提高转染效率和瘤向,显示出癌症基因治疗的巨大潜力.
CA-PEI/RIP3有效诱导细胞死亡,从而产生强大的免疫反应,这对于癌症免疫疗法至关重要.
这一策略提供了一种安全有效的方法来激活免疫系统对抗瘤,突出其在癌症治疗中的承诺.

关键词:

癌症基因治疗的基因疗法基因输送基因输送基因输送尸体灭 (Necroptosis) 是一种死亡的过程.在RIP3中,它是最重要的.对于pH值敏感的聚合物

更多相关视频

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System

Published on: April 11, 2025

相关概念视频

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.